$17.49 +0.52 (3.06%)

Axogen, Inc. Common Stock (AXGN)

Axogen, Inc. is a biotechnology company focused on the development and commercialization of surgical grafts to repair, replace, or regenerate peripheral nerve tissue. The company specializes in products aimed at nerve repair and regeneration, providing solutions for nerve injuries resulting from surgery, trauma, and other conditions. Based in Florida, Axogen aims to improve functional outcomes for patients with nerve damage.

Payout Frequency

Dividend History

Pay DateAmountEx-DateRecord Date
February 12, 2010$1.002010-01-272010-01-29
March 11, 2005$0.062005-02-232005-02-25

Dividends Summary

Company News

AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
Benzinga • Business Wire • October 1, 2025

The Schall Law Firm is investigating potential securities law violations by Axogen, Inc. after the company's stock dropped over 9% following an FDA application extension announcement for its Avance® Nerve Graft.

Global Amniotic Membrane Market Poised for Extraordinary Growth at a CAGR of ~7% by 2032 | DelveInsight
GlobeNewswire Inc. • Delveinsight • July 30, 2025

The global amniotic membrane market is expected to grow at a 7% CAGR by 2032, driven by increasing demand for advanced wound healing treatments and ophthalmological applications, with North America leading market expansion.

CGM Sensor Demand Likely to Drive DexCom (DXCM) Q2 Earnings - Zacks Investment Research
Zacks Investment Research • Na • July 23, 2024

DexCom, Inc. is scheduled to release its second-quarter 2024 results on July 25. The company's revenues are expected to grow 19% year-over-year, driven by increased product volume and global awareness of its continuous glucose monitoring system. However, rising costs and competition may have weighed on its performance.

AxoGen, inc (AXGN) Q3 2021 Earnings Call Transcript
The Motley Fool [email protected] (Motley Fool Transcribers) • November 4, 2021

AXGN earnings call for the period ending September 30, 2021.